STAT3/5-dependent IL9 overexpression contributes to neoplastic cell survival in mycosis fungoides

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

STAT3/5-dependent IL9 overexpression contributes to neoplastic cell survival in mycosis fungoides. / Vieyra-Garcia, Pablo A.; Wei, Tianling; Naym, David Gram; Fredholm, Simon; Fink-Puches, Regina; Cerroni, Lorenzo; Odum, Niels; O'Malley, John T.; Gniadecki, Robert; Wolf, Peter.

I: Clinical Cancer Research, Bind 22, Nr. 13, 07.2016, s. 3328-3339.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Vieyra-Garcia, PA, Wei, T, Naym, DG, Fredholm, S, Fink-Puches, R, Cerroni, L, Odum, N, O'Malley, JT, Gniadecki, R & Wolf, P 2016, 'STAT3/5-dependent IL9 overexpression contributes to neoplastic cell survival in mycosis fungoides', Clinical Cancer Research, bind 22, nr. 13, s. 3328-3339. https://doi.org/10.1158/1078-0432.CCR-15-1784

APA

Vieyra-Garcia, P. A., Wei, T., Naym, D. G., Fredholm, S., Fink-Puches, R., Cerroni, L., Odum, N., O'Malley, J. T., Gniadecki, R., & Wolf, P. (2016). STAT3/5-dependent IL9 overexpression contributes to neoplastic cell survival in mycosis fungoides. Clinical Cancer Research, 22(13), 3328-3339. https://doi.org/10.1158/1078-0432.CCR-15-1784

Vancouver

Vieyra-Garcia PA, Wei T, Naym DG, Fredholm S, Fink-Puches R, Cerroni L o.a. STAT3/5-dependent IL9 overexpression contributes to neoplastic cell survival in mycosis fungoides. Clinical Cancer Research. 2016 jul.;22(13):3328-3339. https://doi.org/10.1158/1078-0432.CCR-15-1784

Author

Vieyra-Garcia, Pablo A. ; Wei, Tianling ; Naym, David Gram ; Fredholm, Simon ; Fink-Puches, Regina ; Cerroni, Lorenzo ; Odum, Niels ; O'Malley, John T. ; Gniadecki, Robert ; Wolf, Peter. / STAT3/5-dependent IL9 overexpression contributes to neoplastic cell survival in mycosis fungoides. I: Clinical Cancer Research. 2016 ; Bind 22, Nr. 13. s. 3328-3339.

Bibtex

@article{dec95d26780645be996769b611114b2e,
title = "STAT3/5-dependent IL9 overexpression contributes to neoplastic cell survival in mycosis fungoides",
abstract = "Purpose: Sustained inflammation is a key feature of mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL). Resident IL9-producing T cells have been found in skin infections and certain inflammatory skin diseases, but their role in MF is currently unknown. Experimental Design: We analyzed lesional skin from patients with MF for the expression of IL9 and its regulators. To determine which cells were producing IL9, high-throughput sequencing was used to identify malignant clones and Vb-specific antibodies were employed to visualize malignant cells in histologic preparations. To explore the mechanism of IL9 secretion, we knocked down STAT3/5 and IRF4 by siRNA transfection in CTCL cell lines receiving psoralen+UVA (PUVA) ± anti-IL9 antibody. To further examine the role of IL9 in tumor development, the EL-4 T-cell lymphoma model was used in C57BL/6 mice. Results: Malignant and reactive T cells produce IL9 in lesional skin. Expression of the Th9 transcription factor IRF4 in malignant cells was heterogeneous, whereas reactive T cells expressed it uniformly. PUVA or UVB phototherapy diminished the frequencies of IL9- and IL9r-positive cells, as well as STAT3/5a and IRF4 expression in lesional skin. IL9 production was regulated by STAT3/5 and silencing of STAT5 or blockade of IL9 with neutralizing antibodies potentiated cell death after PUVA treatment in vitro. IL9-depleted mice exhibited a reduction of tumor growth, higher frequencies of regulatory T cells, and activated CD4 and CD8 T lymphocytes. Conclusions: Our results suggest that IL9 and its regulators are promising new targets for therapy development in mycosis fungoides.",
author = "Vieyra-Garcia, {Pablo A.} and Tianling Wei and Naym, {David Gram} and Simon Fredholm and Regina Fink-Puches and Lorenzo Cerroni and Niels Odum and O'Malley, {John T.} and Robert Gniadecki and Peter Wolf",
year = "2016",
month = jul,
doi = "10.1158/1078-0432.CCR-15-1784",
language = "English",
volume = "22",
pages = "3328--3339",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research (A A C R)",
number = "13",

}

RIS

TY - JOUR

T1 - STAT3/5-dependent IL9 overexpression contributes to neoplastic cell survival in mycosis fungoides

AU - Vieyra-Garcia, Pablo A.

AU - Wei, Tianling

AU - Naym, David Gram

AU - Fredholm, Simon

AU - Fink-Puches, Regina

AU - Cerroni, Lorenzo

AU - Odum, Niels

AU - O'Malley, John T.

AU - Gniadecki, Robert

AU - Wolf, Peter

PY - 2016/7

Y1 - 2016/7

N2 - Purpose: Sustained inflammation is a key feature of mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL). Resident IL9-producing T cells have been found in skin infections and certain inflammatory skin diseases, but their role in MF is currently unknown. Experimental Design: We analyzed lesional skin from patients with MF for the expression of IL9 and its regulators. To determine which cells were producing IL9, high-throughput sequencing was used to identify malignant clones and Vb-specific antibodies were employed to visualize malignant cells in histologic preparations. To explore the mechanism of IL9 secretion, we knocked down STAT3/5 and IRF4 by siRNA transfection in CTCL cell lines receiving psoralen+UVA (PUVA) ± anti-IL9 antibody. To further examine the role of IL9 in tumor development, the EL-4 T-cell lymphoma model was used in C57BL/6 mice. Results: Malignant and reactive T cells produce IL9 in lesional skin. Expression of the Th9 transcription factor IRF4 in malignant cells was heterogeneous, whereas reactive T cells expressed it uniformly. PUVA or UVB phototherapy diminished the frequencies of IL9- and IL9r-positive cells, as well as STAT3/5a and IRF4 expression in lesional skin. IL9 production was regulated by STAT3/5 and silencing of STAT5 or blockade of IL9 with neutralizing antibodies potentiated cell death after PUVA treatment in vitro. IL9-depleted mice exhibited a reduction of tumor growth, higher frequencies of regulatory T cells, and activated CD4 and CD8 T lymphocytes. Conclusions: Our results suggest that IL9 and its regulators are promising new targets for therapy development in mycosis fungoides.

AB - Purpose: Sustained inflammation is a key feature of mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL). Resident IL9-producing T cells have been found in skin infections and certain inflammatory skin diseases, but their role in MF is currently unknown. Experimental Design: We analyzed lesional skin from patients with MF for the expression of IL9 and its regulators. To determine which cells were producing IL9, high-throughput sequencing was used to identify malignant clones and Vb-specific antibodies were employed to visualize malignant cells in histologic preparations. To explore the mechanism of IL9 secretion, we knocked down STAT3/5 and IRF4 by siRNA transfection in CTCL cell lines receiving psoralen+UVA (PUVA) ± anti-IL9 antibody. To further examine the role of IL9 in tumor development, the EL-4 T-cell lymphoma model was used in C57BL/6 mice. Results: Malignant and reactive T cells produce IL9 in lesional skin. Expression of the Th9 transcription factor IRF4 in malignant cells was heterogeneous, whereas reactive T cells expressed it uniformly. PUVA or UVB phototherapy diminished the frequencies of IL9- and IL9r-positive cells, as well as STAT3/5a and IRF4 expression in lesional skin. IL9 production was regulated by STAT3/5 and silencing of STAT5 or blockade of IL9 with neutralizing antibodies potentiated cell death after PUVA treatment in vitro. IL9-depleted mice exhibited a reduction of tumor growth, higher frequencies of regulatory T cells, and activated CD4 and CD8 T lymphocytes. Conclusions: Our results suggest that IL9 and its regulators are promising new targets for therapy development in mycosis fungoides.

U2 - 10.1158/1078-0432.CCR-15-1784

DO - 10.1158/1078-0432.CCR-15-1784

M3 - Journal article

C2 - 26851186

AN - SCOPUS:84977074370

VL - 22

SP - 3328

EP - 3339

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -

ID: 168909333